POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Myelofibrosis drug combo trial halted early
Disease control TerminatedThis phase 3 trial tested whether adding parsaclisib to the standard drug ruxolitinib could better shrink enlarged spleens and ease symptoms in people with myelofibrosis. The study enrolled 252 participants but was terminated early, so we do not have full results. The combination…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 23, 2026 19:35 UTC
-
New combo therapy aims to shrink spleen and ease symptoms in hard-to-treat myelofibrosis
Disease control TerminatedThis study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
New hope for myelofibrosis patients who failed standard therapy?
Disease control TerminatedThis study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial w…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC